Severe and treatment resistant depression often requires more than standard antidepressants. Two of the most effective interventional options are electroconvulsive therapy and ketamine based treatments. While both are known to reduce depressive symptoms, clinicians and patients often ask a critical question. Which one works faster, and does timing really matter?
A new systematic review and meta analysis published in 2026 takes a closer look at ECT vs ketamine for depression by focusing on how symptoms change over time rather than only examining final outcomes. This time sensitive approach helps explain why earlier studies sometimes reached conflicting conclusions.
Why Timing Is Critical in Severe Depression
For individuals experiencing profound depression, speed of improvement can be lifesaving. Rapid symptom relief may reduce suicide risk, shorten hospital stays, and help patients regain daily functioning sooner. Traditional comparisons between ECT and ketamine have often focused on overall symptom reduction without accounting for how quickly those changes occur.
This new analysis directly addresses that limitation by treating time as a central variable rather than a background detail.
How the Study Compared ECT vs Ketamine for Depression
Researchers systematically reviewed studies comparing electroconvulsive therapy with parenteral ketamine in adults with major depressive disorder. To be included, studies had to measure depressive symptoms at multiple time points and use comparable treatment durations.
Seven studies involving 731 participants met these criteria. The researchers applied a mixed effects meta regression model that adjusted for baseline symptom severity and incorporated time as a fixed effect. This approach allowed them to estimate not only whether patients improved, but how rapidly that improvement occurred.
Key Findings on Speed of Improvement
At the beginning of treatment, patients receiving ketamine showed slightly lower depression scores than those receiving ECT. This reflects ketamine’s well documented rapid antidepressant effects, which can appear within hours or days.
When time was taken into account, a different pattern emerged. ECT produced a faster rate of symptom improvement across the treatment course. On average, ECT was associated with an additional improvement of approximately 0.02 standardized mean difference per day compared to ketamine.
Over a four week period, this difference accumulated into a moderate advantage for ECT. By the end of treatment, ECT demonstrated greater overall symptom reduction despite ketamine’s early benefit.
What This Means for Patients and Clinicians
These findings suggest that both treatments are effective, but they may serve different clinical purposes. Ketamine may be particularly valuable when immediate symptom relief is critical, such as during acute suicidal crises or severe agitation.
ECT, by contrast, appears to provide more consistent and accelerating benefits over time. For patients who can tolerate anesthesia and the procedure itself, ECT may offer stronger symptom reduction across a full treatment course.
Importantly, this does not imply that one approach is universally superior. Instead, it highlights the importance of aligning treatment choice with clinical urgency, patient preference, medical risk, and access to care.
Why This Study Helps Resolve Past Confusion
Previous meta analyses have alternately favored ketamine or ECT, contributing to confusion in clinical decision making. This inconsistency likely reflects differences in when outcomes were measured.
By explicitly modeling time, this study shows that early effects and later effects tell different stories. Ketamine may outperform early, while ECT may deliver greater benefit over time.
In short, ketamine may win the sprint, while ECT may win the marathon.
Looking Ahead in Interventional Psychiatry
As interventional psychiatry continues to evolve, time based analyses like this may become increasingly important. Understanding how quickly treatments work, not just whether they work, can support better shared decision making and more personalized care.
Future research may explore combined or sequential strategies, such as using ketamine for rapid stabilization followed by ECT or other neurostimulation approaches for sustained recovery. For now, this study offers a clearer framework for discussing ECT vs ketamine for depression with patients and care teams.
Citations
Nikolin S, Massaneda Tuneu C, Brettell L, Loo C. Time matters for metas: a systematic review and meta analysis of ECT vs ketamine for depression. Translational Psychiatry. 2026.
https://doi.org/10.1038/s41398-026-03806-z
Rhee TG, Shim SR, Forester BP, et al. Efficacy and safety of ketamine vs electroconvulsive therapy among patients with major depressive episode: a systematic review and meta analysis. JAMA Psychiatry. 2022;79(12):1162–1172.
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2798649